FDA approves infant combo vaccine for meningitis

(AP) — The first vaccine that protects children as young as six weeks against two potentially deadly bacterial infections has won approval from U.S. health regulators.

The Food and Drug Administration approved Menhibrix, a combination vaccine for infants and babies that prevents meningococcal disease and haemophilus influenza. Those bacteria can cause potentially deadly illness, or lead to blindness, mental retardation and amputation.

The FDA said the diseases are difficult to spot because their symptoms are similar to the common cold.

The vaccine is given in a four-dose regimen beginning as early as six weeks of age. The fourth dose can be given as late as 18 months of age.

The is manufactured by GlaxoSmithKline PLC at facilities in Belgium.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Sanofi gets expanded meningitis vaccine approval

Apr 25, 2011

(AP) -- Sanofi Pasteur, the vaccines division of Sanofi-Aventis, said Monday the Food and Drug Administration approved the company's bacterial meningitis vaccine Menactra for children between the ages of 9 months and 23 months.

FDA expands meningitis vaccine approval

Oct 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

FDA approves first 4-in-1 flu vaccine

Feb 29, 2012

Federal health officials have approved the first vaccine that protects against four strains of the common flu, offering one additional layer of protection against the influenza virus that affects millions each year.

Recommended for you

Boxed warnings are common in novel therapeutics

22 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments